ReShape Lifesciences Inc. (RSLS)
Pre-market:
| Previous close | 0.1670 |
| Open | 0.1690 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.1670 - 0.1732 |
| 52-week range | 0.1410 - 2.7980 |
| Volume | |
| Avg. volume | 512,616 |
| Market cap | 3.999M |
| Beta (5Y monthly) | 1.30 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.9100 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.00 |
Simply Wall St.ReShape Lifesciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
ReShape Lifesciences ( NASDAQ:RSLS ) Full Year 2023 Results Key Financial Results Revenue: US$8.68m (down 23% from FY...
GlobeNewswireReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update
Completed First Surgeries With Next-Generation Lap-Band® 2.0 FLEX 2024 Operating Expenses Expected to Decrease by more than 50% Compared to 2023; Reaffirming Commitment to Profitability Conference Call to be Held at 4:30 pm ET Today IRVINE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023
- GlobeNewswire
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
Patent Significantly Strengthens Intellectual Property PortfolioIRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/370,819, entitled, “Intragastric Device.” When issued, the patent will cover claims for an intragastric balloon system, compr
